Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 6;14(1):160.
doi: 10.1186/s13643-025-02902-3.

Effects of photobiomodulation on multiple health outcomes: an umbrella review of randomized clinical trials

Affiliations

Effects of photobiomodulation on multiple health outcomes: an umbrella review of randomized clinical trials

Yejun Son et al. Syst Rev. .

Abstract

Background: Photobiomodulation (PBM) is a non-invasive therapy increasingly used for pain, inflammation, and tissue repair, yet a comprehensive synthesis of its effectiveness across multiple health outcomes remains lacking. Herein, we aimed to systematically assess the clinical effects and strength of evidence for PBM across a wide range of health outcomes using data from existing meta-analyses of randomized controlled trials (RCTs).

Methods: We conducted an umbrella review of meta-analyses of RCTs, searching five databases up to December 8, 2023. Two reviewers independently assessed methodological quality using AMSTAR 2 and evaluated certainty of evidence using a modified GRADE framework. Pooled effect sizes were recalculated as equivalent standardized mean differences (eSMD) with 95% confidence intervals (CI). The study was registered with PROSPERO (CRD42023495502).

Results: A total of 15 meta-analyses encompassing 204 RCTs and over 9000 participants were included, covering 35 health endpoints across 15 disease conditions. PBM showed significant effects for 12 outcomes, with moderate certainty of evidence supporting improvements in burning mouth syndrome (pain reduction, eSMD - 0.92 [95% CI - 1.38 to - 0.46]), knee osteoarthritis (disability, 0.65 [0.14 to 1.15]), fibromyalgia (fatigue, 1.25 [0.63 to 1.87]), androgenetic alopecia (hair density, 1.32 [1.00 to 1.63]), and cognitive function (0.49 [0.14 to 0.84]). Most other outcomes exhibited low or very low certainty due to heterogeneity or small-study effects. P-curve and funnel plot analyses indicated evidential value for several outcomes, though potential publication bias was identified in some.

Conclusions: PBM appeared beneficial for some health conditions, such as the strongest support for fibromyalgia, osteoarthritis-related disability, and cognitive impairment. However, given the overall low-to-moderate certainty of evidence for most endpoints, further high-quality trials and standardization of PBM protocols are warranted before widespread clinical adoption.

Keywords: Health outcomes; Low-level light therapy; Photobiomodulation; Randomized controlled trials; Umbrella review.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: An ethics statement is not applicable because this study is based exclusively on published literature. In its reporting, this manuscript follows PRISMA 2020 Guideline. Consent for publication: This article does not contain any studies with human participants or animals performed by any of the authors. This paper is a systematic review of published literature, so ethical approval and consent were not required. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA 2020 flow diagram. Abbreviations: RCT, randomized controlled trials
Fig. 2
Fig. 2
Point estimates of health outcomes following PBM intervention. Abbreviations: CI, confidence interval; eSMD, equivalent standard mean difference; FIQ, fibromyalgia impact questionnaire; PBM, photobiomodulation; THI, Tinnitus Handicap Inventory; VAS, visual analogue scale

Similar articles

References

    1. Herkes G, McGee C, Liebert A, Bicknell B, Isaac V, Kiat H, McLachlan CS. A novel transcranial photobiomodulation device to address motor signs of Parkinson’s disease: a parallel randomised feasibility study. EClinicalMedicine. 2023;66:102338. - PMC - PubMed
    1. Figueiro Longo MG, Tan CO, Chan ST, Welt J, Avesta A, Ratai E, Mercaldo ND, Yendiki A, Namati J, Chico-Calero I, et al. Effect of transcranial low-level light therapy vs sham therapy among patients with moderate traumatic brain injury: a randomized clinical trial. JAMA Netw Open. 2020;3(9):e2017337. - PMC - PubMed
    1. Behroozian T, Goldshtein D, Ryan Wolf J, van den Hurk C, Finkelstein S, Lam H, Patel P, Kanee L, Lee SF, Chan AW, et al. MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review. EClinicalMedicine. 2023;58:101886. - PMC - PubMed
    1. Pigatto GR, Silva CS, Parizotto NA. Photobiomodulation therapy reduces acute pain and inflammation in mice. J Photochem Photobiol B. 2019;196:111513. - PubMed
    1. Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4(6):651–62. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources